Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis
March 31st 2025, 5:00pm
Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.
Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma
March 31st 2025, 4:54pm
Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.
Dr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AML
March 31st 2025, 4:51pm
Esther Natalie Oliva, MD, discusses the rationale for the phase 3 QuANTUM-Wild trial in newly diagnosed FLT3-ITD–negative AML.
Hematologists Highlight Top Abstracts to Watch at the 2025 EBMT Annual Meeting
March 28th 2025, 2:00pm
Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.
Nirogacestat Provides Long-Term Benefits in Desmoid Tumors
March 27th 2025, 8:00pm
ESMO Sarcoma and Rare Cancers Congress
Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.
Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas
March 27th 2025, 6:00pm
ESMO Sarcoma and Rare Cancers Congress
Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.
Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
March 27th 2025, 12:12pm
Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.
Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG
March 24th 2025, 10:05pm
ESMO Sarcoma and Rare Cancers Congress
A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.
Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma
March 24th 2025, 6:58pm
ESMO Sarcoma and Rare Cancers Congress
A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.
Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL
March 23rd 2025, 10:00am
Transplantation and Cellular Therapy Meetings
The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.
First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC
March 21st 2025, 12:00pm
Genitourinary Cancers Symposium (ASCO GU)
Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.
Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer
March 19th 2025, 5:00pm
Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.
Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer
March 18th 2025, 8:04pm
Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.
Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC
March 18th 2025, 1:35pm
Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.
Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer
March 18th 2025, 5:36am
Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.
Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer
March 18th 2025, 5:31am
Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer
March 17th 2025, 9:20pm
The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.
Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer
March 17th 2025, 9:04pm
Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
March 17th 2025, 8:50pm
Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.
Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer
March 17th 2025, 7:49pm
The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.